S&P 500   3,925.74 (-3.99%)
DOW   31,501.37 (-3.53%)
QQQ   291.25 (-4.87%)
AAPL   140.33 (-5.97%)
MSFT   254.70 (-4.54%)
FB   193.85 (-4.33%)
GOOGL   2,251.84 (-3.33%)
AMZN   2,145.85 (-7.00%)
TSLA   703.88 (-7.58%)
NVDA   169.46 (-6.77%)
BABA   87.63 (-4.74%)
NIO   15.76 (-5.23%)
AMD   96.46 (-5.87%)
CGC   5.62 (-4.58%)
MU   70.78 (-4.97%)
T   20.22 (-1.70%)
GE   74.95 (-1.90%)
F   12.80 (-5.40%)
DIS   104.73 (-3.60%)
AMC   12.72 (-1.40%)
PFE   50.32 (-1.99%)
PYPL   77.15 (-3.26%)
NFLX   178.21 (-6.48%)
S&P 500   3,925.74 (-3.99%)
DOW   31,501.37 (-3.53%)
QQQ   291.25 (-4.87%)
AAPL   140.33 (-5.97%)
MSFT   254.70 (-4.54%)
FB   193.85 (-4.33%)
GOOGL   2,251.84 (-3.33%)
AMZN   2,145.85 (-7.00%)
TSLA   703.88 (-7.58%)
NVDA   169.46 (-6.77%)
BABA   87.63 (-4.74%)
NIO   15.76 (-5.23%)
AMD   96.46 (-5.87%)
CGC   5.62 (-4.58%)
MU   70.78 (-4.97%)
T   20.22 (-1.70%)
GE   74.95 (-1.90%)
F   12.80 (-5.40%)
DIS   104.73 (-3.60%)
AMC   12.72 (-1.40%)
PFE   50.32 (-1.99%)
PYPL   77.15 (-3.26%)
NFLX   178.21 (-6.48%)
S&P 500   3,925.74 (-3.99%)
DOW   31,501.37 (-3.53%)
QQQ   291.25 (-4.87%)
AAPL   140.33 (-5.97%)
MSFT   254.70 (-4.54%)
FB   193.85 (-4.33%)
GOOGL   2,251.84 (-3.33%)
AMZN   2,145.85 (-7.00%)
TSLA   703.88 (-7.58%)
NVDA   169.46 (-6.77%)
BABA   87.63 (-4.74%)
NIO   15.76 (-5.23%)
AMD   96.46 (-5.87%)
CGC   5.62 (-4.58%)
MU   70.78 (-4.97%)
T   20.22 (-1.70%)
GE   74.95 (-1.90%)
F   12.80 (-5.40%)
DIS   104.73 (-3.60%)
AMC   12.72 (-1.40%)
PFE   50.32 (-1.99%)
PYPL   77.15 (-3.26%)
NFLX   178.21 (-6.48%)
S&P 500   3,925.74 (-3.99%)
DOW   31,501.37 (-3.53%)
QQQ   291.25 (-4.87%)
AAPL   140.33 (-5.97%)
MSFT   254.70 (-4.54%)
FB   193.85 (-4.33%)
GOOGL   2,251.84 (-3.33%)
AMZN   2,145.85 (-7.00%)
TSLA   703.88 (-7.58%)
NVDA   169.46 (-6.77%)
BABA   87.63 (-4.74%)
NIO   15.76 (-5.23%)
AMD   96.46 (-5.87%)
CGC   5.62 (-4.58%)
MU   70.78 (-4.97%)
T   20.22 (-1.70%)
GE   74.95 (-1.90%)
F   12.80 (-5.40%)
DIS   104.73 (-3.60%)
AMC   12.72 (-1.40%)
PFE   50.32 (-1.99%)
PYPL   77.15 (-3.26%)
NFLX   178.21 (-6.48%)
NASDAQ:ADTX

Aditxt (ADTX) Stock Forecast, Price & News

$0.26
-0.01 (-3.70%)
(As of 05/18/2022 02:43 PM ET)
Add
Compare
Today's Range
$0.26
$0.27
50-Day Range
$0.27
$0.52
52-Week Range
$0.24
$3.95
Volume
1,804 shs
Average Volume
235,090 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.2
30 days | 90 days | 365 days | Advanced Chart
Receive ADTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter.

Aditxt logo

About Aditxt

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Headlines

Aditxt Submits Two EUA's For AditxtScore For COVID-19 - Quick Facts
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADTX
Fax
N/A
Employees
58
Year Founded
N/A

Sales & Book Value

Annual Sales
$110 thousand
Book Value
$0.23 per share

Profitability

Net Income
$-46.37 million
Pretax Margin
-44,148.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
40,804,000
Market Cap
$11.63 million
Optionable
Not Optionable

Company Calendar

Last Earnings
8/11/2021
Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.83 out of 5 stars

Medical Sector

1301st out of 1,426 stocks

Pharmaceutical Preparations Industry

640th out of 680 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Aditxt (NASDAQ:ADTX) Frequently Asked Questions

Are investors shorting Aditxt?

Aditxt saw a drop in short interest in April. As of April 30th, there was short interest totaling 403,500 shares, a drop of 55.2% from the April 15th total of 900,800 shares. Based on an average trading volume of 577,800 shares, the short-interest ratio is currently 0.7 days.
View Aditxt's Short Interest
.

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) announced its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.37.
View Aditxt's earnings history
.

Who are Aditxt's key executives?
Aditxt's management team includes the following people:
  • Mr. Amro A. Albanna, Co-Founder, Chairman & CEO (Age 52, Pay $750k)
  • Ms. Corinne D. Pankovcin CPA, CPA, M.B.A., Pres (Age 56, Pay $583.25k) (LinkedIn Profile)
  • Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D., Co-Founder, Chief Innovation Officer, Sec. & Director (Age 59, Pay $455k) (LinkedIn Profile)
  • Mr. Thomas J. Farley CPA, Chief Financial Officer (Age 48, Pay $522k) (LinkedIn Profile)
  • Ms. Rowena Albanna, Chief Operating Officer (Age 56)
  • Mr. Matthew M. Shatzkes, Chief Legal Officer & Gen. Counsel
  • Ms. Jennifer Lee, Director of HR
  • Dr. Dolly B. Tyan Ph.D., Sr. VP of Clinical Devel. – Transplantation
  • Dr. Joachim-Friedrich Kapp M.D., Ph.D., Sr. VP of Clinical Devel. - Autoimmunity (Age 80)
What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Square (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).

What is Aditxt's stock symbol?

Aditxt trades on the NASDAQ under the ticker symbol "ADTX."

Who are Aditxt's major shareholders?

Aditxt's stock is owned by a variety of institutional and retail investors. Top institutional investors include Inspire Advisors LLC (0.51%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Aditxt stock include Corinne Pankovcin, Shahrokh Shabahang and Thomas J Farley.
View institutional ownership trends for Aditxt
.

Which institutional investors are buying Aditxt stock?

ADTX stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC, and Inspire Advisors LLC. Company insiders that have bought Aditxt stock in the last two years include Corinne Pankovcin, Shahrokh Shabahang, and Thomas J Farley.
View insider buying and selling activity for Aditxt
or or view top insider-buying stocks.

How do I buy shares of Aditxt?

Shares of ADTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aditxt's stock price today?

One share of ADTX stock can currently be purchased for approximately $0.26.

How much money does Aditxt make?

Aditxt has a market capitalization of $11.63 million and generates $110 thousand in revenue each year.

How many employees does Aditxt have?

Aditxt employs 58 workers across the globe.

What is Aditxt's official website?

The official website for Aditxt is www.aditxt.com.

How can I contact Aditxt?

Aditxt's mailing address is 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043. The company can be reached via phone at 650-870-1200 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.